Compare Novo Nordisk A/S (NVO) vs iShares 20 Plus Year Treasury Bond ETF (TLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs iShares 20 Plus Year Treasury Bond ETF — how do they compare? Novo Nordisk A/S trades at $47.23 (market cap $207.85B), while iShares 20 Plus Year Treasury Bond ETF trades at $82.08. The key difference: Novo Nordisk A/S pays a 3.81% dividend while iShares 20 Plus Year Treasury Bond ETF pays none, and Novo Nordisk A/S is trading nearer its 52-week high, iShares 20 Plus Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| NVO | TLT | |
|---|---|---|
Market Cap | $207.85B | — |
Sector | Health | — |
52-Week High | $63.98 | $92.06 |
52-Week Low | $35.29 | $82.05 |
Enterprise Value | $222.55B | — |
Dividend Yield | 3.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
TLT, the iShares 20+ Year Treasury Bond ETF, trades at $82.29 with a slight 0.3% daily gain amid bearish technical signals. The ETF faces pressure from rising long-term Treasury yields, with the 30-year yield recently hitting 5.24% (The Motley Fool, 2026-08-02). Institutional interest persists as Ferguson Shapiro LLC acquired 37,900 shares (Defense World, 2026-08-10), but outflows and U.S. debt nearing $40 trillion weigh on sentiment.
Outlook remains cautious as higher yields and inflation concerns challenge TLT's performance. Opportunities exist for income-focused investors given dividend payments, but risks include Fed rate hike potential and escalating geopolitical tensions driving oil prices higher. The bearish technical setup suggests continued pressure unless bond market sentiment improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About iShares 20 Plus Year Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.
Read more on TLT →
